Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1/2
- “This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).”In the company’s words, NCT07285694 on ClinicalTrials.gov
Other drugs for Metastatic Castration Resistant Prostate Cancer (mCRPC)
- PasritamigJohnson & Johnson (Janssen) · Phase 3
- JNJ-87189401Johnson & Johnson (Janssen) · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- AAA617Novartis · Phase 2
- JSB462Novartis · Phase 2
- GedatolisibCelcuity Inc · Phase 1/2
Coming up0
No dates coming up.
Changes2
Last 90 days- 16 NovStatus changed: Active, not recruiting to Terminated · ClinicalTrials.gov NCT07285694
- 16 NovCompletion date moved: 2029-05 to 2026-10-19 · ClinicalTrials.gov NCT07285694
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Terminated | 19 Oct 2026 | AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026